Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer.
Saif
Muhammad Wasif
MW
Ramos
Jorge
J
Knisely
Jonathan
J
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000532:radiotherapy; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000068258:Bevacizumab; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004382:Duodenitis / Q000139:chemically induced*; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000209:etiology; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D011855:Radiodermatitis / Q000139:chemically induced*; D013276:Stomach Ulcer / Q000139:chemically induced*; D000093542:Gemcitabine
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000068258:Bevacizumab; D000093542:Gemcitabine